Warning letter
LifeSouth Community Blood Centers, Inc.: warning letter of Jan 30, 2012
FDA warning letter 252076 · New Orleans District Office
Key facts
| Reference number | 252076 |
|---|---|
| Company | LifeSouth Community Blood Centers, Inc. |
| Subject | CGMP for Blood & Blood Products/Adulterated |
| Issue date | Jan 30, 2012 |
| Posted date | Jan 30, 2012 |
| Issuing office | New Orleans District Office |
| Product type | Biologics |
| CFR sections cited | 606.20(b), 606.65(e), 606.100(c), 606.160(b)(3)(i), 606.165(b), 640.11(a) |
| Inspection city | Madison |
| Inspection ZIP | 35758 |
| Inspection start date | Oct 17, 2011 |
| Letter on fda.gov | web.archive.org |
At a glance
- 1–9 CFR sections cited
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: